The upcoming CompCancer Seminar will be hosted by Bettina Schmidt. Find the invitation below. The link is available from compcancer at charite dot de.
Dear PI's and fellow students,
in our next CompCancer seminar on Wednesday, 2nd of June at 10 AM, please welcome Bernd Bodenmiller, who will talk about his newly published paper (19.5.21, Cell Systems) https://www.sciencedirect.com/science/article/pii/S2405471221001113 on drug-sensitivity prediction based on signaling pathways in breast cancer.
It is interesting for you if you work on
#signaling pathways #CyTOF #drug-sensitivity prediction #bigdata #MANOVA #precision medicine
and I'm sure many different things that I did not capture. Feel free to forward this information to people who could be interested
One goal of precision medicine is to tailor effective treatments to patients’ specific molecular markers of disease. Here, we used mass cytometry to characterize the single-cell signaling landscapes of 62 breast cancer cell lines and five lines from healthy tissue. We quantified 34 markers in each cell line upon stimulation by the growth factor EGF in the presence or absence of five kinase inhibitors. These data—on more than 80 million single cells from 4,000 conditions—were used to fit mechanistic signaling network models that provide insight into how cancer cells process information. Our dynamic single-cell-based models accurately predicted drug sensitivity and identified genomic features associated with drug sensitivity, including a missense mutation in DDIT3 predictive of PI3K-inhibition sensitivity. We observed similar trends in genotype-drug sensitivity associations in patient-derived xenograft mouse models. This work provides proof of principle that patient-specific single-cell measurements and modeling could inform effective precision medicine strategies.
See you then,